drugset / Trial / NCT01896830

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan

NCT01896830 ↗

Phase 1/2 Completed 102 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupSingle-blindPrevention

Summary

The aim of the study is to evaluate a candidate C. difficile Toxoid Vaccine in the Japanese population. Primary objectives: * To describe the safety profile of all subjects who receive at least 1 injection * To describe the immunogenicity to toxin A and toxin B in all subjects from serum samples obtained on Days 0, 14, 30, and 60.

Timeline

Start
2013-07
Primary completion
2013-10
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Clostridium difficile toxoid vaccine Vaccine 0.5 ml Intramuscular